HRP20192009T1 - Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a - Google Patents
Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a Download PDFInfo
- Publication number
- HRP20192009T1 HRP20192009T1 HRP20192009TT HRP20192009T HRP20192009T1 HR P20192009 T1 HRP20192009 T1 HR P20192009T1 HR P20192009T T HRP20192009T T HR P20192009TT HR P20192009 T HRP20192009 T HR P20192009T HR P20192009 T1 HRP20192009 T1 HR P20192009T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- hydroxy
- isoxazol
- butanamide
- methylsulfonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Spoj formule (I):
ili njegova farmaceutski prihvatljiva sol, pri čemu:
X je -NH- i R1 je -CH(OH)-Y;
ili
X je -CH2- i R1 je -CH(OH)-Y ili -SO2R2 gdje je R2 C1-C3 alkil;
R3 je H ili halo;
Y je odabran iz 5-članog heteroaril prstena koji sadrži 1-3 heteroatoma odabranih između N, O i S kao članova prstena, fenila i C1-3 alkila i svaki Y je opcionalno supstituiran s jednim do tri R4;
svaki R4 je neovisno odabran između halo, C1-3 alkila i C3-6 cikloalkila, pri čemu C1-3 alkil i C3-6 cikloalkil su svaki opcionalno supstituirani sa do tri skupine odabrane između halo, CN i –OH;
L je -C≡C- ili -CR5=CR5-;
R5 je neovisno odabran pri svakom pojavljivanju između H, halo i metila;
i
Z je odabran između C1-6 alkila, C3-C6 cikloalkila, piridinila i fenila, od kojih je svaki opcionalno supstituiran sa do tri skupine odabrane između halogena, hidroksi, C1-4 alkoksi, C1-4 haloalkoksi, CN i C1-4 alkila koji je opcionalno supstituiran s jednom do tri skupina odabranih između halogena, hidroksi, amino, CN i C1-3 alkoksi;
ili, kada je L -CR5=CR5-, Z uzet zajedno s jednom od R5 skupina i bilo koji atomi koji povezuju Z s R5 skupinom mogu tvoriti 3-7-članu cikloalkil ili cikloalkenil skupinu koja je opcionalno supstituirana sa do tri skupine odabrane između halogena, hidroksi, C1-4 alkoksi, C1-4 haloalkoksi, CN i C1-4 alkila koji je opcionalno supstituiran s jednom do tri skupina odabranih između halogena, hidroksi, amino, CN i C1-3 alkoksi.
2. Spoj u skladu s patentnim zahtjevom 1, pri čemu je R1 -SO2R2.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, pri čemu je X -CH2-.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu je Z C1-C4 alkil ili C3-C6 cikloalkil
i Z je opcionalno supstituiran sa do tri skupine odabrane između halogena, C1-4 alkoksi, C1-4 haloalkoksi, CN i C1-4 alkila opcionalno supstituiranih s jednom do tri skupina odabranih između halogena, hidroksi, amino, CN i C1-3 alkoksi.
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je L -C=C- .
6. Spoj u skladu s patentnim zahtjevom 1, pri čemu je spoj formule (II):
7. Spoj u skladu s patentnim zahtjevom 1, pri čemu je spoj odabran iz skupine koja se sastoji od
(R)-4-(5-(ciklopropiletinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-(ciklobutiletinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-(3,3-dimetilbut-1-in-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-2-metil-2-(metilsulfonil)-4-(5-(prop-1-in-1-il)izoksazol-3-il)butanamida,
(R)-4-(5-(but-1-in-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-2-metil-4-(5-(3-metilbut-1-in-1-il)izoksazol-3-il)-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-2-metil-2-(metilsulfonil)-4-(5-(pent-1-in-1-il)izoksazol-3-il)butanamida,
(R)-N-hidroksi-2-metil-4-(5-((1-metilciklopropil)etinil)izoksazol-3-il)-2-(metilsulfonil)butanamida,
(R)-4-(5-(5-fluorobut-1-in-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-(5-fluoropent-1-in-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-(5,5-difluoropent-1-in-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-((3,3-difluor)etinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-((3-fluorociklobutil)etinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-4-(5-(5-hidroksi-5-metilheks-1-in-1-il)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-4-(5-((3-(metoksimetil)ciklobutil)etinil)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-4-(5-((3-(2-hidroksipropan-2-il)ciklobutil)etinil)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
N-hidroksi-4-(5-((4-(hidroksimetil)fenil)etinil)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
N-hidroksi-4-(5-((4-(2-hidroksietil)fenil)etinil)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
N-hidroksi-4-(5-((4-(2-hidroksi-1-metoksietil)fenil)etinil)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
N-hidroksi-2-metil-2-(metilsulfonil)-4-(5-(feniletinil)izoksazol-3-il)butanamida,
N-hidroksi-4-(5-((4-((R)-2-hidroksipropil)fenil)etinil)izoksazol-3-il)-2-metil-2-(metilsulfonil)butanamida,
(R)-N-hidroksi-4-(5-((4-((S)-2-hidroksi-1-metoksietil)fenil)etinil)-izoksazol-3-il)-2-metil-2-(metilsulfonil)-butanamida,
(R)-4-(5-((4-((S)-1,2-dihidroksietil)fenil)etinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(R)-4-(5-((4-((R)-1,2-dihidroksietil)fenil)etinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamida,
(2S,3R)-2-(((5-(ciklopropiletinil)izoksazol-3-il)metil)amino)-N,3-dihidroksi-2-metil-3-(5-metilizoksazol-3-il)propanamid,
(2S,3R)-2-(((5-(ciklobutiletinil)izoksazol-3-il)metil)amino)-N,3-dihidroksi-2-metil-3-(5-metilizoksazol-3-il)propanamid,
(2S,3R)-N,3-dihidroksi-2-metil-3-(5-metilizoksazol-3-il)-2-(((5-(feniletinil)izoksazol-3-il)metil)amino)propanamid,
N,3-dihidroksi-3-(5-(hidroksimetil)izoksazol-3-il)-2-metil-2-(((5-(feniletinil)izoksazol-3-il)metil)amino)propanamid,
(2S,3R)-N,3-dihidroksi-2-(((5-(6-metoksiheks-1-in-1-il)izoksazol-3-il)metil)amino)-2-metil-3-(5-metilizoksazol-3-il)propanamid,
2-(((5-(ciklopropiletilin) izoksazol-3-il)metil)amino)-3-(5-ciklopropilizoksazol-3-il)-N,3-dihidroksi-2-metilpropanamid,
(R,E)-4-(5-(but-1-en-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid,
(R,E)-4-(5-(2-ciklopropilvinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid,
(R,E)-4-(5-(but-2-en-2-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid,
(R,Z)-4-(5-(but-2-en-2-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid,
(R,Z)-4-(5-(2-ciklopropil-1-fluorovinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid,
(R,E)-4-(5-(2-ciklopropil-1-fluorovinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid,
(R,Z)-4-(5-(2-ciklopropil-2-fluorovinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid i
(R)-4-(5-(cikloheks-1-en-1-il)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid
ili njegova farmaceutski prihvatljiva sol.
8. Spoj u skladu s patentnim zahtjevom 1, koji je
(R)-4-(5-(ciklopropiletinil)izoksazol-3-il)-N-hidroksi-2-metil-2-(metilsulfonil)butanamid
ili njegova farmaceutski prihvatljiva sol.
9. Farmaceutski pripravak, koji sadrži:
spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8 i
farmaceutski prihvatljiv nosač.
10. Farmaceutska kombinacija, koja sadrži:
spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8,
antibakterijski učinkovitu količinu drugog terapeutskog sredstva i
farmaceutski prihvatljiv nosač.
11. Farmaceutska kombinacija u skladu s patentnim zahtjevom 10, pri čemu je drugo terapeutsko sredstvo odabrano iz skupine koja se sastoji od ampicilina, piperacilina, penicilina G, tikarcilina, imipenema, meropenema, azitromicina, eritromicina, aztreonama, cefepima, cefotaksima, ceftriaksona, ceftazidima, ciprofloksacina, levofloksacina, klindamicina, doksiciklina, gentamicina, amikacina, tobramicina, tetraciklina, tigeciklina, rifampicina, vankomicina i polimiksina.
12. Spoj u skladu s patentnim zahtjevima 1 do 8 ili njegova farmaceutski prihvatljiva sol, za uporabu kao lijek.
13. Spoj u skladu s patentnim zahtjevima 1 do 8 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju gram–negativne bakterijske infekcije.
14. Spoj u skladu s patentnim zahtjevima 1 do 8 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju gram–negativne bakterijske infekcije, pri čemu je bakterijska infekcija odabrana iz vrsta Pseudomonadales i Enterobacteriaceae koje su odabrane iz skupine koja se sastoji od vrsta Pseudomonas, Acinetobacter, Stenotrophomonas, Burkholderia, Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Shigella, Providencia, Morganella, Cedecea, Yersina i Edwardsiella i Escherichia coli.
15. Spoj za uporabu u skladu s patentnim zahtjevom 13, pri čemu se spoj formule (I) koristi u kombinaciji s imunomodulatorom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092402P | 2014-12-16 | 2014-12-16 | |
| PCT/IB2015/059631 WO2016097995A1 (en) | 2014-12-16 | 2015-12-15 | Isoxazole hydroxamic acid compounds as lpxc inhibitors |
| EP15816893.0A EP3233843B1 (en) | 2014-12-16 | 2015-12-15 | Isoxazole hydroxamic acid compounds as lpxc inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192009T1 true HRP20192009T1 (hr) | 2020-02-07 |
Family
ID=55025302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192009TT HRP20192009T1 (hr) | 2014-12-16 | 2015-12-15 | Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a |
Country Status (42)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200527A1 (es) | 2013-05-17 | 2020-03-09 | Incyte Corp | Derivados del bipirazol como inhibidores jak |
| HRP20201524T1 (hr) * | 2016-06-14 | 2021-03-05 | Novartis Ag | Kristalni oblik (r)-4-(5-(ciklopropiletinil) izoksazol-3 -il)-n-hidroksi-2-metil-2-(metilsufonil) butanamid kao antibakterijsko sredstvo |
| CN107434766A (zh) * | 2017-08-09 | 2017-12-05 | 凯莱英医药集团（天津）股份有限公司 | 烷烃羟胺类化合物的合成装置及连续合成方法 |
| UA127519C2 (uk) | 2018-02-16 | 2023-09-20 | Інсайт Корпорейшн | Інгібітори шляху jak1, призначені для лікування порушень, пов'язаних із цитокінами |
| CA3113226A1 (en) | 2018-09-20 | 2020-03-26 | Forge Therapeutics, Inc. | Antibacterial compounds |
| TW202039478A (zh) * | 2018-11-21 | 2020-11-01 | 日商大正製藥股份有限公司 | 新穎咪唑衍生物 |
| JP7802696B2 (ja) | 2020-06-02 | 2026-01-20 | インサイト・コーポレイション | Ｊａｋ１阻害剤の調製プロセス |
| JP2023552452A (ja) | 2020-12-08 | 2023-12-15 | インサイト・コーポレイション | 白斑治療用のｊａｋ１経路阻害薬 |
| CN112603936B (zh) * | 2020-12-28 | 2022-08-02 | 仲恺农业工程学院 | 一种抑制气单胞菌属的组合物及其制备方法与应用 |
| WO2022173756A1 (en) * | 2021-02-11 | 2022-08-18 | Forge Therapeutics, Inc. | Antibacterial compounds |
| TW202246218A (zh) * | 2021-02-11 | 2022-12-01 | 美商福吉醫療公司 | 抗菌化合物 |
| EP4696710A3 (en) | 2021-05-03 | 2026-05-06 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| CA3233328A1 (en) * | 2021-09-28 | 2023-04-06 | Min Teng | Lpxc inhibitors and uses thereof |
| WO2024067812A1 (zh) * | 2022-09-28 | 2024-04-04 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
| US20260092055A1 (en) * | 2022-09-28 | 2026-04-02 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3381783D1 (de) | 1982-03-03 | 1990-09-13 | Genentech Inc | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
| DE59009528D1 (de) | 1989-09-22 | 1995-09-21 | Basf Ag | Carbonsäureamide. |
| DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| WO1999020758A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
| PT1196186E (pt) | 1999-07-12 | 2008-02-14 | Genentech Inc | Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral. |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| SG159388A1 (en) | 2003-01-08 | 2010-03-30 | Chiron Corp | Antibacterial agents |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| US8722686B2 (en) * | 2008-09-19 | 2014-05-13 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| CA2774250C (en) * | 2009-10-13 | 2013-12-17 | Pfizer Inc. | C-linked hydroxamic acid derivatives useful as antibacterial agents |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2512474T3 (pl) * | 2009-12-16 | 2015-03-31 | Pfizer | N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| US8877754B2 (en) | 2010-09-06 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| AR083760A1 (es) | 2010-11-10 | 2013-03-20 | Achaogen Inc | Agentes antibacterianos y composiciones farmaceuticas |
| GEP20156370B (en) | 2011-03-07 | 2015-09-25 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
| EP2694488B1 (en) * | 2011-04-08 | 2014-11-12 | Pfizer Inc | Isoxazole derivatives useful as antibacterial agents |
| EP2694481B1 (en) * | 2011-04-08 | 2015-12-30 | Pfizer Inc | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014160649A1 (en) | 2013-03-29 | 2014-10-02 | Novartis Ag | Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections |
-
2015
- 2015-12-15 CU CU2017000084A patent/CU24443B1/es unknown
- 2015-12-15 AU AU2015365455A patent/AU2015365455B2/en not_active Ceased
- 2015-12-15 LT LT15816893T patent/LT3233843T/lt unknown
- 2015-12-15 PT PT158168930T patent/PT3233843T/pt unknown
- 2015-12-15 US US14/969,930 patent/US9549916B2/en not_active Expired - Fee Related
- 2015-12-15 PE PE2017001078A patent/PE20171044A1/es unknown
- 2015-12-15 WO PCT/IB2015/059631 patent/WO2016097995A1/en not_active Ceased
- 2015-12-15 SI SI201530987T patent/SI3233843T1/sl unknown
- 2015-12-15 EA EA201791353A patent/EA032138B1/ru not_active IP Right Cessation
- 2015-12-15 ES ES15816893T patent/ES2756300T3/es active Active
- 2015-12-15 PL PL15816893T patent/PL3233843T3/pl unknown
- 2015-12-15 MX MX2017007980A patent/MX2017007980A/es active IP Right Grant
- 2015-12-15 ME MEP-2019-305A patent/ME03546B/me unknown
- 2015-12-15 TN TN2017000207A patent/TN2017000207A1/en unknown
- 2015-12-15 MY MYPI2017701741A patent/MY195743A/en unknown
- 2015-12-15 TW TW104142164A patent/TWI693215B/zh not_active IP Right Cessation
- 2015-12-15 EP EP15816893.0A patent/EP3233843B1/en active Active
- 2015-12-15 UA UAA201705042A patent/UA121225C2/uk unknown
- 2015-12-15 SG SG11201704053WA patent/SG11201704053WA/en unknown
- 2015-12-15 CR CR20170260A patent/CR20170260A/es unknown
- 2015-12-15 CA CA2969803A patent/CA2969803A1/en not_active Abandoned
- 2015-12-15 MA MA41185A patent/MA41185B1/fr unknown
- 2015-12-15 HU HUE15816893A patent/HUE047225T2/hu unknown
- 2015-12-15 HR HRP20192009TT patent/HRP20192009T1/hr unknown
- 2015-12-15 SM SM20190631T patent/SMT201900631T1/it unknown
- 2015-12-15 DK DK15816893T patent/DK3233843T3/da active
- 2015-12-15 JP JP2017532143A patent/JP6697466B2/ja not_active Expired - Fee Related
- 2015-12-15 RS RS20191403A patent/RS59507B1/sr unknown
- 2015-12-15 KR KR1020177016102A patent/KR20170094214A/ko not_active Withdrawn
- 2015-12-15 CN CN201580066726.8A patent/CN107001295B/zh not_active Expired - Fee Related
- 2015-12-15 BR BR112017011422-4A patent/BR112017011422A2/pt not_active IP Right Cessation
- 2015-12-16 AR ARP150104119A patent/AR107428A1/es unknown
- 2015-12-16 UY UY0001036448A patent/UY36448A/es not_active Application Discontinuation
- 2015-12-16 JO JOP/2015/0318A patent/JO3818B1/ar active
-
2016
- 2016-12-12 US US15/375,560 patent/US9815804B2/en not_active Expired - Fee Related
-
2017
- 2017-05-18 IL IL25237317A patent/IL252373B/en active IP Right Grant
- 2017-06-01 PH PH12017501019A patent/PH12017501019B1/en unknown
- 2017-06-08 CL CL2017001460A patent/CL2017001460A1/es unknown
- 2017-06-14 CO CONC2017/0005870A patent/CO2017005870A2/es unknown
- 2017-06-16 GT GT201700132A patent/GT201700132A/es unknown
- 2017-06-16 SV SV2017005462A patent/SV2017005462A/es unknown
- 2017-07-16 EC ECIEPI201745737A patent/ECSP17045737A/es unknown
- 2017-10-09 US US15/728,351 patent/US10029994B2/en active Active
-
2019
- 2019-11-11 CY CY20191101181T patent/CY1122305T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513892A5 (hr) | ||
| JP2016535758A5 (hr) | ||
| PH12022551137A1 (en) | Novel salt of terphenyl compound | |
| AR048306A1 (es) | Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40 | |
| PE20191147A1 (es) | Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador | |
| JOP20190182B1 (ar) | أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga | |
| JP2015520769A5 (hr) | ||
| PE20090434A1 (es) | Derivados de sulfonil amida como inhibidores de quinasas | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| SI2182950T1 (en) | Use of 4- (pyrrolidin-1-yl) quinoline compounds for killing clinically latent microorganisms | |
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| HRP20151405T1 (hr) | Novi supstituirani kinolinski spojevi kao inhibitori reduktaze s-nitrosoglutationa | |
| JP2016505619A5 (hr) | ||
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| PE20141148A1 (es) | Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| HRP20140884T1 (hr) | Derivati fenoksipiridinilamida i njihova primjena u lijeäśenju bolesnih stanja posredovanih inhibitorima pde4 | |
| JP2011526594A5 (hr) | ||
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| PH12020551345A1 (en) | 2,4-diaminoquinazoline derivatives and medical uses thereof | |
| RU2011104223A (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| PE20110069A1 (es) | Compuestos de tetraciclina sustituidos | |
| HRP20220026T1 (hr) | Derivati izoksazola kao agonisti nuklearnog receptora i njihove uporabe | |
| RU2015138443A (ru) | Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2 | |
| PH12014500831A1 (en) | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives |